Author

Damian Szczesny

Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdansk, Gdansk, Poland;

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Beata Filip-PsurskaiD· 1 shared David K Crossman· 1 shared Eliza Turlej· 1 shared James F Collawn· 1 shared Joanna Wietrzyk· 1 shared Karol Krzyminski· 1 shared Katarzyna Wierzbicka· 1 shared Leszek Kalinowski· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Beata Filip-PsurskaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Preclinical Evaluation of a Novel BOC-Modified Triazoloacridinone (TRA-01AR) in Combination with 5-Fluorouracil in Colorectal Cancer

Marta Switalska, Paulina Czechowicz, Magdalena Milczarek, Sylwia Bartoszewska, Beata Filip-Psurska, Katarzyna Wierzbicka, Mateusz Psurski, Damian Szczesny, Eliza Turlej, Karol Krzyminski, Malgorzata Gawronska, Magdalena Gebert, Leszek Kalinowski, David K Crossman, Maciej Baginski, , Joanna Wietrzyk

This study evaluates the combination of 5-FU with two triazoloacridinones, C-1305 and TRA-01AR, in CRC, finding that C-1305 shows greater antitumor activity while TRA-01AR has improved tolerability and vascular effects.

bioRxiv · Nov 10, 2026 · PreprintPharmacology & Toxicology